<DOC>
	<DOCNO>NCT01889641</DOCNO>
	<brief_summary>Treatment multisystemic form lupus display severe side effect limit efficacy , underscore need good dissection pathogenic mechanism . Concordant preliminary data , IL26 signal could impair systemic lupus . Moreover , IL 26 could marker disease activity potential therapeutic target . In present study , serum IL 26 level lupus patient control measure .</brief_summary>
	<brief_title>IL-26 Systemic Lupus Erythematosus</brief_title>
	<detailed_description />
	<criteria>diagnostic Lupus accord ACR criterion ( four criterion necessary ) age &gt; 18 year old treatment cyclophosphamide , rituximab , belimumab year inclusion study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>